We also saw similar effects in an imatinib-treated KIT-mutant GIST cell line (Fig. 2c; Supplementary Fig. 2c), MET-dependent cell lines or ALK-mutant cells treated with the MET/ALK inhibitor crizotinib (Supplementary Fig. 2d, e), a HER2-amplified breast cancer cell line treated with HER2 inhibitor lapatinib (Supplementary Fig. 2f), and an EGFR-mutant lung cancer cell line treated with the EGFR inhibitor gefitinib (Supplementary Fig. 2g). Here, ERBB2 is linked to breast carcinoma.